CAMBRIDGE, Mass.--(BUSINESS WIRE)--
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine
platform company developing targeted and programmable therapeutics
called AccurinsTM, today announced that Greg Berk, M.D.,
Chief Medical Officer, will be leaving BIND to pursue another
opportunity. Dr. Berk will serve as an advisor to BIND after his
"Our clinical team is focused on the Phase 2 clinical trials for our
lead product candidate, BIND-014, which continues to enroll patients in
line with our expectations," commented Scott Minick, President and Chief
Executive Officer of BIND. "We look forward to reporting clinical
results and our progress on developing the platform later this year."
"BIND's Accurin platform represents an exciting opportunity, and I have
very much enjoyed the experience of working with the accomplished BIND
team to translate this technology into the robust clinical program that
is ongoing today," said Dr. Berk. "I remain enthusiastic about the
potential clinical benefit that BIND-014 can bring to patients and look
forward to remaining involved in an advisory role."
The Company is initiating a search for a new chief medical officer.
Edward Schnipper, M.D., who has been serving as an advisor to BIND and
formerly served as BIND's chief medical officer, will serve as the
company's chief medical officer on an interim basis.
About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company
developing Accurins, its novel targeted therapeutics. BIND intends to
leverage its Medicinal Nanoengineering® platform to develop a
pipeline of Accurins, initially in oncology, as well as Accurins in
collaboration with biopharmaceutical companies. BIND's lead drug
candidate, BIND-014, is an Accurin that targets PSMA and contains
docetaxel, a clinically-validated and widely used cancer chemotherapy
drug. BIND-014 is currently in Phase 2 clinical trials for non-small
cell lung cancer and metastatic castrate-resistant prostate cancer. BIND
has announced collaborations with Amgen Inc., Pfizer Inc. and
AstraZeneca AB to develop Accurins based on therapeutic payloads from
their product pipelines. BIND's platform originated from the pioneering
nanotechnology research at the Massachusetts Institute of Technology and
Brigham and Women's Hospital/Harvard Medical School of BIND's scientific
founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For
more information, please visit the company's web site at www.bindtherapeutics.com.
Source: BIND Therapeutics, Inc.